Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777246 | 0.91 | CTSK (0.49) | ATMABCB1CTSSCTSKMMP13 | |
| SCHEMBL29846348 | 0.88 | CTSS (0.43) | S1PR3ATMABCB1CTSSCTSK | |
| SCHEMBL28588129 | 0.87 | CTSL (0.45) | S1PR3ATMABCB1CTSSCTSK | |
| SCHEMBL12838215 | 0.86 | NPC1 (0.49) | ABCB1PPARACTSSCTSKPPARG | |
| SCHEMBL10217082 | 0.82 | ATM (0.43) | ATMABCB1PPARACTSSCTSK | |
| SCHEMBL20522011 | 0.81 | CNR1 (0.48) | ATMMAPTCNR1ALDH1A1 | |
| SCHEMBL10089904 | 0.80 | ABCB1 (0.41) | ATMABCB1CTSSCTSKMMP13 | |
| SCHEMBL12293491 | 0.80 | NAMPT (0.48) | ATMABCB1CTSSCTSKMAPT | |
| SCHEMBL6915011 | 0.79 | CYP3A4 (0.45) | ATMCTSSCTSKMMP13CA1 | |
| SCHEMBL7413346 | 0.78 | ABCB1 (0.47) | ATMABCB1PPARACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-06 | — | — | US | disclosed |
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-03 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | ASTEX THERAPEUTICS LIMITED (GB) | 2023-03-14 | — | — | US | disclosed |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077526-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | MDM2, TP53, TP53BP1 | S1PR3 4662/4885ATM 527/4885ABCB1 2303/4885 |
| US-11603367-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them | MDM2, TP53, TP53BP1 | S1PR3 4662/4885ATM 527/4885ABCB1 2303/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | S1PR3 4662/4885ATM 527/4885ABCB1 2303/4885 |
| US-20250074900-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | S1PR3 4662/4885ATM 527/4885ABCB1 2303/4885 |
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | S1PR3 4662/4885ATM 527/4885ABCB1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.